Funding for this research was provided by:
National Institute on Drug Abuse (R01DA038466, P30DA027828)
National Institute of Mental Health (R01MH072961, R01MH092950)
Agency for Healthcare Research and Quality (F32HS024192)
Received: 14 February 2017
Accepted: 18 August 2017
First Online: 6 September 2017
Ethics approval and consent to participate
: Not applicable.
: Not applicable
: GAA is an Associate Editor and CHB is on the Editorial Board of Implementation Science. All decisions on this paper were made by another editor. NB receives salary support from a subcontract from the University of Chicago that is supported by Gilead, the maker of PrEP, which is mentioned in this paper. The authors declare that they have no other competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.